ClinicalTrials.gg
Status unknownNCT02020226Updated Jun 2, 2016

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of TH-302 in Solid Tumors, sponsored by Threshold Pharmaceuticals. Status unknown at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-02.

Sponsored by Threshold Pharmaceuticals · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2016), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The Primary objective of this study is:

  1. To determine the cardiac safety of TH-302 in patients with advanced solid tumors

The Secondary objectives are:

  1. To assess the pharmacokinetics (PK) of TH-302
  2. To evaluate whether there is an association between plasma exposure to TH-302 and its active metabolite, Br-IPM, and effects on cardiac repolarization
  3. To assess the safety and antitumor activity of TH-302 in patients with advanced solid tumors
Read the detailed description

This is an open-label study in patients with advanced solid tumors treated with TH-302 to assess safety, pharmacokinetics, and potential effects on cardiac repolarization and antitumor activity in patients with advanced solid tumors.

A dose of 480 mg/m2 of TH 302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. Evaluations of safety, PK, and ECG parameters of cardiac repolarization will be performed on Study Day 1 and Day 2 of Cycle 1.

Cycles will be repeated every 28 days, until toxicity, progressive disease, patient or investigator decision to discontinue treatment, or until a maximum of six treatment cycles. Patients who are clearly benefitting from the treatment based on anti-cancer disease control and tolerability will be able to continue to receive drug past 6 cycles after discussion with the Sponsor. Tumor assessments will be performed after every 2 cycles during treatment.

The rationale for conducting this study is based on (a) prior data demonstrating the clinical benefit in advanced solid tumors as defined by tumor response or stable disease for at least 4 months, (b) tolerability of TH-302 at the proposed dose, and (c) a requirement to perform a dedicated ECG study to address the clinical evaluation of the potential for QT/QTc interval prolongation of TH-302.

02

Conditions studied

  • Solid Tumors

Keywords

  • TH-302
  • Solid Tumors
  • QTc
  • Cardiac
  • Evofosfamide
03

In context

Lead sponsor

Threshold Pharmaceuticals is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female patients at least 18 years of age
  • Advanced solid tumor for which no other higher priority therapies are available
  • performance status of ) to 1
  • Measurable or evaluable disease by 1.1
  • to standard therapy, relapsed after standard therapy, or have no standard therapy that increases survival at least 3 months
  • At least 3 weeks from previous cytotoxic chemotherapy or radiation therapy and at least 5 half-lives or 6 weeks, which ever is shorter, after targeted or biologic therapy
  • Acceptable renal function defined as serum creatinine ≤ 1.5 times or calculated ≥ 60mL/min (by Cockcroft Gault formula)
  • Acceptable liver function defined as:

    • ≤ 1.5 x upper limit of normal (ULN); does not apply to patients with Gilbert's syndrome
    • (SGOT) and ALT (SGPT) ≤ 3.0 x ULN); if liver are present, then ≤ 5 x ULN is allowed
  • Adequate bone marrow function ( (ANC) ≥ 1,500 cells/uL; (PLT) ≥ 100,000 cells/uL)
  • Adequate cardiac conduction by without evidence of second- or third-degree atrioventricular block and meeting all of the following ECG criteria:

    • Heart rate 45-100 beats per minute
    • No evidence of second- or third-degree atrioventricular block
    • QRS interval ≤ 110ms
    • corrected for heart rate by Fridericia's formula (QTcF) ≤ 480ms
    • PR interval ≤ 200ms
    • No arrhythmia interpreted by the study cardiologist to be
  • Female patients of childbearing age must have a negative serum HCG test unless prior hysterectomy or menopause (defined as age ≥ 55 and twelve consecutive months without menstrual activity). Female patients should not become pregnant or breast-feed while on this study. Sexually active male and female patients should use effective

Exclusion criteria

Exclusion Criteria:

  • Receiving -prolonging drugs with a risk of causing torsades de pointes (TdP), unless meets inclusion criteria on a stable dose of the drug and with discussion and agreement with the project clinician
  • History of risk factors for TdP, including family history of long QT syndrome
  • Sustained systolic blood pressure (BP) >140 mm Hg or \<90 mm Hg, diastolic BP >100 mm Hg or \<60 mm Hg
  • Uncontrolled intercurrent illness, including, but not limited to, myocardial infarction within 6 months, unstable symptomatic ischemic heart disease, active uncontrolled infection requiring systemic therapy, or psychiatric illness/social situations that would limit compliance with study requirements
  • Major surgery within the 28 days preceding the first dose of study drug
  • Newly diagnosed or uncontrolled cancer-related central nervous system disease
  • Receiving medications that are moderate or strong inhibitors or inducers of or that are sensitive substrate or substrates with a narrow therapeutic index of CYP3A4, CYP2D6, or CYP2C9 (see Appendix D)
  • Unwillingness or inability to provide written and comply with the study protocol for any reason
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    TH-302

    480 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle

    Drug: TH-302

Interventions

  • DrugTH-302

    480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle

06

What researchers measure

Primary outcomes

  1. Evaluate the potential for QT/QTc interval prolongation of TH-302 in patients with solid tumors

    Time frame: 2 years

Secondary outcomes

  1. Evaluate association between plasma exposure to TH-302 and its active metabolite, Br-IPM, and effects on cardiac repolarization

    Time frame: 2 years

  2. Safety and antitumor activity of TH-302 in patients with advanced solid tumors

    Time frame: 2 years

07

Study locations

2 sites
  • The University of Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • Yuma Regional Cancer Center
    Yuma, Arizona 85364, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Jul 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2013
First posted
Dec 24, 2013
Start
Nov 2013
Primary completionEst.
Jul 2016
CompletionEst.
Dec 2016
Last update
Jun 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02020226
Lead sponsor
Threshold Pharmaceuticals
Responsible party
Sponsor
First posted
Dec 24, 2013
Start date
Nov 2013
Primary completion
Jul 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Jun 2, 2016

Study contacts

Lee Cranmer, MD, PhD
principal investigator · The University of Arizona Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TH 302

Start the discussion